＜Research＞Jefferies: WUXI BIO (02269.HK) Is Now at Inflection Point from PB Ratio Perspective

　　Jefferies issued a research report saying that WUXI BIO (02269.HK) +0.720 (+5.099%) Short selling $29.50M; Ratio 5.798% is now at an inflection point from a PB ratio perspective, and believing that its risk and reward profile is tipping towards more upside than downside. Therefore, Jefferies rated WUXI BIO at Buy, with a target price of $53.

　　Investors are coming to a consensus on the geopolitical issues faced by WUXI BIO, Jefferies added. As the US Biosecure Act progresses, there will be more clarity to come, especially on how existing contracts will be handled.

　　(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2024-05-08 16:25.)

　　Related NewsCMS Downgrades WUXI BIO (02269.HK) to Neutral, Slashes TP to $13

　　AAStocks Financial News